08.06.2022 • Product

Oqema to Distribute Patcham FZC Product Groups in Europe

Oqema Group, a leading chemical distributor in Europe, has been appointed as the official European distribution partner by Patcham FZC, manufacturer of specialty additives, for their range of products for the paints & inks industry. The distribution agreement covers sales and marketing activities for all European countries, except the UK, Poland, and Italy (partly Baltics) and complements Oqema’s existing specialty product portfolio.

Patcham FZC is a global manufacturer of specialty additives. Since its inception in 1996, the company has steadily grown to become a leading supplier of metal carboxylates and specialty additives for coatings, inks, PVC, composites and oilfield chemicals, as well as tin and tin-free catalysts. Patcham has built a strong manufacturing and R&D infrastructure that enables the rapid transition from concept to products.

“We are delighted that Patcham trusts in our capabilities and has appointed the Oqema Group as their strategic partner in Europe. With Patcham’s specialty additives for the paints & inks industry, we make another massive step to establish Oqema as a leading European distributor for the specialty chemicals industry”, comments André Schommer, Group Business Development Manager.

Company

Logo:

OQEMA AG

Schlossstrasse 39
41352 Korschenbroich
Germany

Company contact







From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read